Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
100 hedge funds and large institutions have $211M invested in Cascadian Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 17 closing their positions.
105% more capital invested
Capital invested by funds: $103M → $211M (+$108M)
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
72% more call options, than puts
Call options by funds: $2.99M | Put options by funds: $1.74M
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more funds holding
Funds holding: 90 → 100 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$11M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.38M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$2.97M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.77M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$12M |
| 2 |
QF
QVT Financial
New York
|
-$10.2M |
| 3 |
BC
Broadfin Capital
New York
|
-$4.75M |
| 4 |
First Eagle Investment Management
New York
|
-$2.12M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.9M |
CASC Hedge Fund Activity: Q2 2015 in Review
100 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2015, worth a combined $211M — up 105% from $103M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CASC positions and 17 closed out — a net gain of 10 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $11M. The largest seller was BVF Inc, cutting an estimated $12M.
- 100 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2015, up from 90 in Q1 2015.
- Funds reported $211M of Cascadian Therapeutics, Inc. stock for Q2 2015, up 105% quarter-over-quarter.
- 27 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2015 and 17 closed out, a net change of +10 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q2 2015 was Redmile Group, an estimated $11M added.
- The largest Cascadian Therapeutics, Inc. seller in Q2 2015 was BVF Inc, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2015.